Huiling Pharmaceutical Consulting (Shanghai) Co., Ltd.

Primary Objective - To demonstrate the bioequivalence of a single dose of 2 g (1 x 2 g) of mesalamine extended-release granules to a single dose of 2 g (4 x 500 mg) of Podesan® tablets under fasting conditions Secondary Objective - To further elucidate the PK properties of mesalamine extended-release granules and Podesan® tablets ? To evaluate the safety and tolerability of mesalamine extended-release granules compared with Podesan® tablets

Primary objective To demonstrate that the pharmacodynamics (PD) of a single 60 μg sublingual dose of desmopressin oral lyophilisate is bioequivalent (BE) to that of a single 0.1 mg oral dose of MiNing tablets Secondary objective To compare the safety and tolerability of a single 60 μg sublingual dose of desmopressin oral lyophilisate and a single 0.1 mg oral dose of MiNing tablets

Primary objective To demonstrate that the pharmacokinetics (AUC and Cmax) of desmopressin oral lyophilisate 240 μg are bioequivalent to that of 0.4 mg oral tablets after a single sublingual administration Secondary objective To compare the AUCt, % Extrap AUC, Frel, λz, tmax and t? of desmopressin oral lyophilisate 240 μg and that of 0.4 mg oral tablets after a single sublingual administration To compare the safety and tolerability of desmopressin oral lyophilisate 240 μg and that of 0.4 mg oral tablets after a single sublingual administration